Broadcast Date: 
  • Time: 

Although mRNA therapeutics have been around in the biopharmaceutical industry for several years, the success of mRNA-based COVID-19 vaccines has fully revealed the potential of this ground-breaking technology. Given the pressure of delivering during a pandemic, vaccine manufacturers have been focused primarily on safety and efficacy, less so how to optimize production and purification processes for future mRNA therapeutics. In fact, the rapid increase in demand for mRNA therapeutics has revealed the inherent challenge of the platform—that the production of mRNA is facing a series of bottlenecks.

In this GEN webinar, we will hear how scientists at Sartorius have been working on streamlining some of the challenges long before the pandemic even started. We will review the real-world pitfalls investigators face in their mRNA manufacturing efforts and how innovative solutions were developed based on deep understanding and the advanced monolithic columns, leading to an extensive product portfolio for mRNA purification. Finally, we will discover how a novel analytical assay based on chromatography can speed up in vitro transcription optimization and process development.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Tomas Kostelec
Tomas Kostelec
Product Manager, mRNA

Sartorius logo